Bias, Corruption & Accountability

An article on contributory injustice describes the clinical and ethical imperative that clinicians listen to service users experiences.

Researchers challenge the recommendation of starting two antidepressants simultaneously to increase preventative effects against suicide.

Historical, current, and potential future complexities of cognitive assessment; a longstanding, controversial fixture in schools throughout the United States.

Scientific freedom and integrity are constantly under attack, particularly in healthcare, which is dominated by the drug industry and other economic interests. To help preserve honesty and integrity in science, the new Institute for Scientific Freedom will open on March 9 with an international meeting in Copenhagen.

A new study has found that children and adolescents taking a high dose of antipsychotics are almost twice as likely to die of any cause than children on other types of medications.

Researchers detect a striking relationship between the month of school enrollment relative to peers and patterns of ADHD diagnoses in a large sample of elementary school students throughout the US.

An international group of researchers, including several with financial ties to manufacturers of antidepressants, explore possible explanations for why long-term users of antidepressants become chronically depressed.

A large and rigorous meta-analysis fails to find support for the gene-environment interaction theory of depression.

A new as-yet-unpublished trial of duloxetine (Cymbalta) for fibromyalgia has presented more evidence of suicidal events in teens.

Researchers discuss the evidence that antipsychotic medications may cause brain atrophy in children, whose brains are still developing.

Between 2007 and 2016, the FDA identified 776 herbal supplements containing active, unapproved pharmaceutical chemicals.

I am just the messenger, the symbol that healthcare is in many ways absurd and harmful because the drug industry is too powerful. The Cochrane Collaboration is in deep crisis because it is too close to industry, practices scientific censorship and has a business model that focuses on “brand” and “our product” rather than getting the science right.

Psychiatrist and psychologist outline pharmacological and psychotherapeutic strategies for discontinuing antidepressants.

The huge impact of the MISTRA, in addition to the harmful and regressive social and political policy implications that flow from it, necessitates a detailed analysis of the “science” behind the study’s major claims and conclusions. Here I offer a new critique of this famous and influential “separated twin study.”

A new study demonstrates how the choice of statistical techniques when examining data plays a large role in scientific outcomes.

A discourse analysis conducted by sociologists finds problematic assumptions and practices in the field of neurocriminology.

A recent review suggests that depression guidelines do not incorporate evidence for exercise within a stepped-care approach and may be over-reliant on pharmacological treatments.

A recent Cochrane review has found that serious adverse events occur for about 1% of children and adolescents treated with Ritalin.

A new report on pediatric bipolar critically examines the current evidence base and calls for more research before the diagnosis is used.

Researchers explore how family interventions for psychosis might be adapted to China’s emerging integrated mental health care landscape.

A new study, published in Psychological Medicine, found evidence for a specific type of publication bias distorting the evidence about antidepressant efficacy.

The "independent report" that investigated the complaints against Peter Gøtzsche (which included a complaint from E. Fuller Torrey) reveals that they arose in connection with his criticisms of psychiatric drugs. The Cochrane Collaboration's ouster of Gøtzsche betrays a commitment to open-minded science that is vital to serving the public good.

A new analysis of antipsychotic treatment of schizophrenia (published in Schizophrenia Bulletin) has found that two-thirds of patients treated this way do not experience symptom remission.

Prominent researchers conduct a review of antidepressant withdrawal incidence, duration, and severity. Results lead to call for new clinical guidelines.

White race and size of initial prescription, along with poor sleep quality, are associated with long-term benzodiazepine use in older adults.